Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept

Davide Giuseppe Ribaldone, Marta Vernero, Marco Astegiano

Research output: Contribution to journalArticlepeer-review

Abstract

We sincerely thank Viscido et al. for their appropriate and sharable comments on our recent study on adalimumab biosimilar ABP 501 in Crohn's disease (CD). The use of a biosimilar in inflammatory disorders is one of the current main topics, given the great opportunity to save resources that can be invested in innovative drugs and the ethical problems that non-medical switching can generate.

Original languageEnglish
Pages (from-to)155
Number of pages1
JournalRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
Volume113
Issue number2
DOIs
Publication statusPublished - Feb 1 2021
Externally publishedYes

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept'. Together they form a unique fingerprint.

Cite this